PBC therapy Ocaliva pulled from EU market with court decision
Ocaliva (obeticholic acid) is no longer available to treat primary biliary cholangitis (PBC) across the European Union (EU), with an earlier decision…
Lindsey Shapiro, PhD, Science Writer — 
Articles by Lindsey Shapiro
Linerixibat eases ‘relentless’ PBC itching in Phase 3 trial, meeting goal
Treatment with linerixibat, an oral medication in development by GlaxoSmithKline (GSK), led to significant reductions in pruritus, or itching, among adults with primary…
Semaglutide shows liver benefits in Phase 3 MASH trial
Weekly injections of semaglutide, a medication sold in the U.S. under brand names including Ozempic and Wegovy to treat type 2 diabetes and obesity, reduced…
Phase 3 trials of treatment combo for hepatitis D expected in 2025
On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed…
Fatty liver disease affects 45% of teens, adults in US, Hispanics most
About 45% of teens and adults in the U.S. have some form of fatty liver disease, with Hispanic populations being more affected than other…
Study uncovers how hepatitis E can lead to kidney damage
Researchers have identified a possible mechanism by which infection with the hepatitis E virus (HEV), a known cause of liver inflammation, can lead to…
American Liver Foundation funds 4 research projects in biliary atresia
The American Liver Foundation (ALF) has announced the eight winners of its 2024 Pilot Research Awards, with four of the awards going to scientist-led…
First-in-human trial of PBGENE-HBV for chronic hepatitis B opens
Precision Biosciences has opened a first-in-human trial testing its gene-editing therapy candidate PBGENE-HBV in people with chronic hepatitis B infections, and says data…
Aligos planning for Phase 2 trial of treatment for hepatitis B
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1 drug-drug interaction study to evaluate the effects of certain drugs…
RTY-694 chosen as lead treatment candidate for liver disease PSC
Rectify Pharmaceuticals has selected the oral small molecule RTY-694 as its lead treatment candidate for primary sclerosing cholangitis (PSC) and plans are underway…
